Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Galecto (Nasdaq: GLTO) announced an inducement equity grant approved by its board on December 15, 2025 and disclosed on December 16, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Galecto (Nasdaq: GLTO) announced an inducement equity grant approved by its board on December 15, 2025 and disclosed on December 16, 2025. The board granted non-qualified stock options to purchase 312,535 shares to one new employee under the company's 2022 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $32.00 per share and vest 25% on the first anniversary of the grant date, then an additional 1/48th each month thereafter, subject to continued employment.
Details
News Market Reaction – GLTO
On Dec 17, the first trading day after this news, GLTO closed 12.23% below the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Option grant size
- 312,535 shares
- Non-qualified stock options under 2022 Inducement Plan
- Exercise price
- $32.00 per share
- Exercise price of inducement stock options
- Grant date
- December 15, 2025
- Grant Date for the inducement stock options
- Initial vesting
- 25%
- Vests on first anniversary of Grant Date
- Ongoing vesting
- 1/48th monthly
- Monthly vesting after first anniversary, subject to employment
Historical Context
-
Damora acquisition plus large private placement extended cash runway into 2029.
-
Q3 results and constructive FDA pre‑IND feedback for GB3226 AML program.
-
Plan to present GB3226 preclinical and development data at ASH 2025.
-
Q2 2025 results with lower expenses and focus on GB3226; shares were flat.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
Nasdaq Listing Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on December 15, 2025 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2022 Inducement Plan, as amended from time to time. The Inducement Grant was granted as an inducement material to this individual entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share equal to
About Galecto
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. The Company expects to submit an IND or equivalent filing for lead asset, DMR-001, a potentially best-in-class, subcutaneously administered monoclonal antibody targeting mutCALR, in mid-2026. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of AML. For regular updates about Galecto, visit www.galecto.com.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Sandya von der Weid
LifeSci
svonderweid@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.